rpg7
24 Nov 2015
Re: sp action Whoops time to upgrade my abacus.
aenigma
23 Nov 2015
Re: sp action I think you'll find it's much fairer than that. £1,560,000
rpg7
23 Nov 2015
Re: sp action Market cap. circa £26,000,000. sp down 6% on the sale of £2000 worth of shares ie £156,000 wiped off market cap.-seems fair!
Pharma Giles
28 Oct 2015
Market Cap I would assume the reduction in Market Cap has several knock on effects. 1. Any term sheet previously agreed a few months ago, would have valued IMM almost double what it is today. Thus a $14M investment today would be worth a larger slice of the IMM post money pie . I'm sure the funder is probably arguing for this?2. The deal with the CRO, to pay part of the service fees in shares @150p per share, seems a little less attractive now to Simbec-Orion I'm sure - given £1m is effectively worth a 1/6th of that at today's share price.3. However if there was a potential licensing partner sitting on the touchline, given the current market cap, it now becomes more attractive (financially and practically) to simply buy the company, rather than enter into the details of a licensing agreement and worry whether both companies will work well together.
Pharma Giles
14 Oct 2015
Re: Recent SP decline Thank you SKSounds like the delay in the study may be raising questions around its funding. Hopefully IMM will reassure investors (again) that the funds have been secured (and ideally in the bank), or even better get first patient into the trial soon. Either way we should hopefully see an upturn when they do either...
sicilian_kan
13 Oct 2015
Re: Recent SP decline Hi. I am just as much in the dark as you.It appears that there has been a serious of events all combining at the same time to cause the drop in the share price
a) There has in the long term been a seller or sellers for some time;(b) There is at least concern that Richard Warr's estate have been sellers;(c) There have at best been delays in the $14m funding as on 27 July 2015 the conversion of the term sheet into a binding agreement was "anticipated in the next few weeks". This has not yet happened, which creates uncertainty and speculation.(d) Possibly as a result of the above clinicaltrials.gov still states that the Lupuzor Phase III trial "is not yet open for participant recruitment"(e) Immupharma is not yet in a position where it has other pipeline drugs (e.g. cancer, other indications of Lupuzor, urelix etc.) that sustain the market cap.(c), (d) and (e) have created the conditions where (a) and (b) can have a more serious impact than they otherwise might.The frustrating thing about this share is that it clearly is massively undervalued. It could without much difficulty 100 bag within circa 2 years if the Phase 3 results match the Phase 2b results. The IMM share price used to reflect this potential. When the company was last heading towards what people thought would be a Phase 3 trial, the share price hit 145p, with just a 20% royalty and some large milestones. Now we have 100% and a better pipeline to fall back on than before.So why is the share price in the doldrums. Well (a) to (e) spell out the short term reasons why. The reality though is that the real reason is a longer term one.One could understand that upon recovery of Lupuzor it would take time to unravel it.One could understand that getting the SPA was important and that it would shape negotiations with Big Pharma.One could understand obtaining the Darwin facility to gain leverage in negotiations.One could understand the appointment of Torreya, who could unlock doors to key people quickly, even if frustrated that the Board's connections and efforts were by default not enough.One could understand that if one couldn't extract the appropriate value for Lupuzor in a licensing deal, that the decision to retain 100% of Lupuzor was the correct one, even if that meant pushing back the multi-bagging.One can understand how the CRO deal / appointment and the setting up of Phase III with them can take some time.One can also understand how the illness and death of Richard Warr might have affected the company, though the new board does look strong.Cumulatively, we are looking at a long period that shareholders have had to wait for Lupuzor to be funded to progress, either by license, sale, partnership or self funding, even if most of that period is explainable.Having gone through the above, we have the US term sheet announced with $14m funding if the agreement is signed and made legally binding. But it has not yet been formalised. We do not know the terms of dilution or the funding facility, how relatively good it might be. We also do not know if or when it will be signed and it appears that there has been some slippage.On the one hand, the Board appears to be protecting our best interest - namely to extract fair value for Lupuzor and not to unnecessarily or to overly dilute our interest in it.On the other hand, if the board does not like selling the Crown jewels for a song, it should not have let IMM get to the stage where it was still negotiating funding as the share price drifts down to a 10 year company low based in part upon a lack of progress.Once funding, in whatever shape or form, is announced, I expect we will see a very good rise and that value will return to shareholders. In the interim, we are at the whim of the sellers and the vagaries of the market and market sentiment. Where that will lead us in the short term, I cannot say. It could be up or down.However, I remain positive that once
Pharma Giles
13 Oct 2015
Recent SP decline I'm still at a loss to see any reason for this. The Phase III study was supposed to start in Sept, but a Phase III starting late is nothing new, so not sure it could be that. Simbec and Orion are CROs, so basically charge on a "fee for service" basis (irrespective of some sort of 150p share option/commitment built in). Even if there was an issue with Simbec/Orion another CRO could be found with relative ease, with little impact on the study outcome (although would delay the start further). Nothing I can see would have such a detrimental effect on IMM that warrants the drop? Bit confused...
sicilian_kan
24 Jul 2015
Phase 3 Starting The Lupuzor phase 3 trial has gone up in the past week on the www.clinicaltrials.gov website. For those not aware, this is the official US National Institutes of Health webpage that details all clinical trials in the US. The link is below:[link] will see that the trial is due to start in September 2015. Each patient will have an injection every four weeks with the expected dose. The primary outcome is efficacy after a year and the webpage gives further details.The estimated date of completion for the primary outcome measure (Final data collection date) is April 2017 with the study completion rate being June 2017. So that means patient recruitment is expected to be complete within 7 months.200 patients are to be enrolled (this will be one of the 200 patient arms of the trial and the FDA is referred to as the Health Authority - presumably the other arm is European).
rpg7
09 Jul 2015
Re: sp action They are still MManipulating the price down on no volume. keeping a record of this for later use.
rpg7
18 May 2015
sp action You couldn't make it up-but wait suMM(sic.) can .The FCA may be interested lol.
aenigma
08 Apr 2015
7.29% Has anyone any idea why this has risen 7% today?
ggamma
12 Mar 2015
Sicilian_kan - Thank you very much for all of the information you provide to this message board. I find it extremely valuable and informative. I am not sure if you've spoke about this in a prior post (if you, I can't seem to locate it). But I was wondering what your thoughts were around the public results for Epratuzumab in SLE? Thnx
festering heap
23 Jan 2015
Re: RNS [link] chief says ‘watch this space’ on further partnerships after inking collaboration deal
festering heap
22 Jan 2015
Re: RNS RNS outLIFT OF !
